Literature DB >> 24197760

Factors associated with local-regional failure after definitive chemoradiation for locally advanced esophageal cancer.

Arya Amini1, Jaffer Ajani, Ritsuko Komaki, Pamela K Allen, Bruce D Minsky, Mariela Blum, Lianchun Xiao, Akihiro Suzuki, Wayne Hofstetter, Stephen Swisher, Daniel Gomez, Zhongxing Liao, Jeffrey H Lee, Manoop S Bhutani, James W Welsh.   

Abstract

BACKGROUND: Locally advanced esophageal cancer is often treated with a trimodality approach. While a substantial proportion of such patients initially achieve a clinical complete response (cCR) after chemoradiation, only a small proportion achieve durable control. We analyzed patients who reached cCR after definitive chemoradiation for esophageal cancer to identify clinical predictors of local disease recurrence.
METHODS: We identified 141 patients who obtained initial cCR after definitive chemoradiation without surgery for esophageal cancer from 2002 through 2009. The initial response to treatment was assessed by endoscopic evaluation and biopsy results, with cCR defined as having no evidence of disease present. Patterns of failure were categorized as in-field (within the planned treatment volume [PTV]), outside the radiation treatment field, or both.
RESULTS: At a median follow-up of 22 months (range, 6-87 months), 77 patients (55 %) had experienced disease recurrence (local or both). Of first failures, 32 (23 %) were outside the radiation field, followed by 30 (21 %) within the field, and 15 (11 %) were both. By multivariate analysis, in-field failure after cCR was associated with a pretreatment standardized uptake value on positron emission tomography of >10 (subhazard ratio [SHR] 3.31, p = 0.023) and poorly differentiated tumors (SHR 3.69, p = 0.031). All failures, in-field and out-of-field, correlated with non-Caucasian ethnicity (SHR 2.55, p = 0.001), N1 disease (SHR 2.05, p = 0.034), T3/T4 disease (SHR 3.56, p = 0.011), and older age (SHR 0.96, p = 0.008).
CONCLUSIONS: Our data suggest that selected clinical characteristics can be used to predict failure patterns after definitive chemoradiation. Such risk-assessment strategies can help individualize therapy.

Entities:  

Mesh:

Year:  2013        PMID: 24197760     DOI: 10.1245/s10434-013-3303-0

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  18 in total

1.  Actionable Locoregional Relapses after Therapy of Localized Esophageal Cancer: Insights from a Large Cohort.

Authors:  Elena Elimova; Xuemei Wang; Wei Qiao; Kazuki Sudo; Roopma Wadhwa; Hironori Shiozaki; Yusuke Shimodaira; Venkatram Planjery; Nikolaos Charalampakis; Jeffrey H Lee; Brian R Weston; Manoop S Bhutani; Ritsuko Komaki; David C Rice; Stephen G Swisher; Mariela A Blum; Jane E Rogers; Heath D Skinner; Dipen M Maru; Wayne L Hofstetter; Jaffer A Ajani
Journal:  Oncology       Date:  2018-04-27       Impact factor: 2.935

Review 2.  Clinical tools to predict outcomes in patients with esophageal cancer treated with definitive chemoradiation: are we there yet?

Authors:  Abraham J Wu; Karyn A Goodman
Journal:  J Gastrointest Oncol       Date:  2015-02

3.  Treatment outcomes according to the macroscopic tumor type in locally advanced esophageal squamous cell carcinoma treated by chemoradiotherapy.

Authors:  Katsumaro Kubo; Koichi Wadasaki; Katsunori Shinozaki
Journal:  Jpn J Radiol       Date:  2019-01-28       Impact factor: 2.374

Review 4.  Definitive chemoradiotherapy.

Authors:  Michael Stahl; Wilfried Budach
Journal:  J Thorac Dis       Date:  2017-07       Impact factor: 2.895

5.  Distribution and timing of distant metastasis after local therapy in a large cohort of patients with esophageal and esophagogastric junction cancer.

Authors:  Hironori Shiozaki; Kazuki Sudo; Lianchun Xiao; Roopma Wadhwa; Elena Elimova; Wayne L Hofstetter; Heath D Skinner; Jeffrey H Lee; Brian Weston; Manoop S Bhutani; Mariela A Blum; Dipen M Maru; Jaffer A Ajani
Journal:  Oncology       Date:  2014-06-07       Impact factor: 2.935

6.  Final Results of NRG Oncology RTOG 0246: An Organ-Preserving Selective Resection Strategy in Esophageal Cancer Patients Treated with Definitive Chemoradiation.

Authors:  Stephen G Swisher; Jennifer Moughan; Ritsuko U Komaki; Jaffer A Ajani; Tsung T Wu; Wayne L Hofstetter; Andre A Konski; Christopher G Willett
Journal:  J Thorac Oncol       Date:  2016-10-08       Impact factor: 15.609

7.  Volumetric modulated arc therapy (VMAT) in the treatment of esophageal cancer patients.

Authors:  Stefania Martini; Francesca Arcadipane; Paolo Strignano; Rosella Spadi; Viviana Contu; Christian Fiandra; Riccardo Ragona; Giorgia Catalano; Maria Antonietta Satolli; Michele Camandona; Renato Romagnoli; Umberto Ricardi; Pierfrancesco Franco
Journal:  Med Oncol       Date:  2018-10-04       Impact factor: 3.064

8.  Involved-field irradiation in definitive chemoradiotherapy for T4 squamous cell carcinoma of the esophagus.

Authors:  M Li; F Zhao; X Zhang; F Shi; H Zhu; A Han; Y Zhang; L Kong; J Yu
Journal:  Curr Oncol       Date:  2016-04-13       Impact factor: 3.677

Review 9.  Salvage esophagectomy.

Authors:  Wayne L Hofstetter
Journal:  J Thorac Dis       Date:  2014-05       Impact factor: 2.895

10.  Importance of surveillance and success of salvage strategies after definitive chemoradiation in patients with esophageal cancer.

Authors:  Kazuki Sudo; Lianchun Xiao; Roopma Wadhwa; Hironori Shiozaki; Elena Elimova; Takashi Taketa; Mariela A Blum; Jeffrey H Lee; Manoop S Bhutani; Brian Weston; William A Ross; Ritsuko Komaki; David C Rice; Stephen G Swisher; Wayne L Hofstetter; Dipen M Maru; Heath D Skinner; Jaffer A Ajani
Journal:  J Clin Oncol       Date:  2014-09-15       Impact factor: 44.544

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.